Screener
10x Genomics, Inc. TXG Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
FAQ
- What is 10x Genomics, Inc.'s cash & equivalents?
- 10x Genomics, Inc. (TXG) reported cash & equivalents of $502.51M in Q2 2026.
- How has 10x Genomics, Inc.'s cash & equivalents changed year-over-year?
- 10x Genomics, Inc.'s cash & equivalents increased by 26.4% year-over-year, from $397.71M to $502.51M.
- What is the long-term trend for 10x Genomics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s cash & equivalents has grown at a -7.2% compound annual growth rate (CAGR), from $688.64M to $473.97M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about 10x Genomics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude